7 results on '"Nghia, Ho D. T."'
Search Results
2. MUC5AC Genetic Variation Is Associated With Tuberculous Meningitis Cerebral Spinal Fluid Cytokine Responses and Mortality.
- Author
-
Sabo, Michelle C, Thuong, Nguyen T T, Chang, Xuling, Ardiansyah, Edwin, Tram, Trinh T B, Hai, Hoang T, Nghia, Ho D T, Bang, Nguyen D, Dian, Sofiati, Ganiem, A Rizal, Shaporifar, Shima, Kumar, Vinod, Li, Zheng, Hibberd, Martin, Khor, Chiea Chuen, Thwaites, Guy E, Heemskerk, Dorothee, Laarhoven, Arjan van, Crevel, Reinout van, and Dunstan, Sarah J
- Subjects
TUBERCULOUS meningitis ,GENETIC variation ,CEREBROSPINAL fluid ,SINGLE nucleotide polymorphisms ,TUMOR necrosis factors - Abstract
Background The purpose of this study was to assess if single nucleotide polymorphisms (SNPs) in lung mucins MUC5B and MUC5AC are associated with Mycobacterium tuberculosis outcomes. Methods Independent SNPs in MUC5B and MUC5AC (genotyped by Illumina HumanOmniExpress array) were assessed for associations with tumor necrosis factor (TNF) concentrations (measured by immunoassay) in cerebral spinal fluid (CSF) from tuberculous meningitis (TBM) patients. SNPs associated with CSF TNF concentrations were carried forward for analyses of pulmonary and meningeal tuberculosis susceptibility and TBM mortality. Results MUC5AC SNP rs28737416 T allele was associated with lower CSF concentrations of TNF (P = 1.8 × 10
−8 ) and IFN-γ (P = 2.3 × 10−6 ). In an additive genetic model, rs28737416 T/T genotype was associated with higher susceptibility to TBM (odds ratio [OR], 1.24; 95% confidence interval [CI], 1.03–1.49; P =.02), but not pulmonary tuberculosis (OR, 1.11, 95% CI,.98–1.25; P =.10). TBM mortality was higher among participants with the rs28737416 T/T and T/C genotypes (35/119, 30.4%) versus the C/C genotype (11/89, 12.4%; log-rank P =.005) in a Vietnam discovery cohort (n = 210), an independent Vietnam validation cohort (n = 87; 9/87, 19.1% vs 1/20, 2.5%; log-rank P =.02), and an Indonesia validation cohort (n = 468, 127/287, 44.3% vs 65/181, 35.9%; log-rank P =.06). Conclusions MUC5AC variants may contribute to immune changes that influence TBM outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
3. A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIVuninfected adults.
- Author
-
Mai, Nguyen T. H., Dobbs, Nicholas, Nguyen Hoan Phu, Colas, Romain A., Thao, Le T. P., Thuong, Nguyen T. T., Nghia, Ho D. T., Hanh, Nguyen H. H., Hang, Nguyen T., Heemskerk, A. Dorothee, Day, Jeremy N., Ly, Lucy, Thu, Do D. A., Merson, Laura, Kestelyn, Evelyne, Wolbers, Marcel, Geskus, Ronald, Summers, David, Chau, Nguyen V. V., and Dalli, Jesmond
- Published
- 2018
- Full Text
- View/download PDF
4. The antimicrobial resistance patterns and associated determinants in Streptococcus suis isolated from humans in southern Vietnam, 1997-2008.
- Author
-
Hoa, Ngo T., Chieu, Tran T. B., Nghia, Ho D. T., Mai, Nguyen T. H., Anh, Pham H., Wolbers, Marcel, Baker, Stephen, Campbell, James I., Chau, Nguyen W., Hien, Tran T., Farrar, Jeremy, and Schultsz, Constance
- Subjects
STREPTOCOCCUS ,MENINGITIS ,ZOONOSES ,TETRACYCLINE ,ERYTHROMYCIN - Abstract
Background: Streptococcus suis is an emerging zoonotic pathogen and is the leading cause of bacterial meningitis in adults in Vietnam. Systematic data on the antimicrobial susceptibility profiles of S. suis strains isolated from human cases are lacking. We studied antimicrobial resistance and associated resistance determinants in S. suis isolated from patients with meningitis in southern Vietnam. Methods: S. suis strains isolated between 1997 and 2008 were investigated for their susceptibility to six antimicrobial agents. Strains were screened for the presence and expression of tetracycline and erythromycin resistance determinants and the association of tet(M) genes with Tn916- like transposons. The localization of tetracycline resistance gene tet(L) was determined by pulse field gel electrophoresis and Southern blotting. Results: We observed a significant increase in resistance to tetracycline and chloramphenicol, which was concurrent with an increase in multi-drug resistance. In tetracycline resistance strains, we identified tet(M), tet(O), tet (W) and tet(L) and confirmed their expression. All tet(M) genes were associated with a Tn916-like transposon. The co-expression of tet(L) and other tetracycline resistance gene(s) encoding for ribosomal protection protein(s) was only detected in strains with a minimum inhibitory concentration (MIC) of tetracycline of ≥ 64 mg/L Conclusions: We demonstrated that multi-drug resistance in S. suis causing disease in humans in southern Vietnam has increased over the 11-year period studied. We report the presence and expression of tet(L) in S. suis strains and our data suggest that co-expression of multiple genes encoding distinct mechanism is required for an MIC ≥ 64 mg/L to tetracycline. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
5. Adjunctive Dexamethasone for Tuberculous Meningitis in HIV-Positive Adults.
- Author
-
Donovan, Joseph, Bang, Nguyen D., Imran, Darma, Nghia, Ho D. T., Burhan, Erlina, Huong, Dau T. T., Hiep, Nguyen T. T., Ngoc, Lam H. B., Thanh, Dang V., Thanh, Nguyen T., Wardhani, Anna L. S., Maharani, Kartika, Gasmara, Cakra P., Hanh, Nguyen H. H., Oanh, Pham K. N., Estiasari, Riwanti, Thu, Do D. A., Kusumaningrum, Ardiana, Dung, Le T., and Giang, Do C.
- Subjects
- *
TUBERCULOUS meningitis , *IMMUNE reconstitution inflammatory syndrome , *HIV-positive persons , *DEXAMETHASONE , *HIV , *CD4 lymphocyte count - Abstract
BACKGROUND: Adjunctive glucocorticoids are widely used to treat human immunodeficiency virus (HIV)-associated tuberculous meningitis despite limited data supporting their safety and efficacy. METHODS: We conducted a double-blind, randomized, placebo-controlled trial involving HIV-positive adults (218 years of age) with tuberculous meningitis in Vietnam and Indonesia. Participants were randomly assigned to receive a 6-to-8-week tapering Apcourse of either dexamethasone or placebo in addition to 12 inonths of asntituber-culosis chemotherapy. The primary end point was death from any cause during the 12 months after randomization. RESULTS: A total of 520 adults were randomly assigned to receive either dexamethasone (263 participants) or placebo (257 participants). The median age was 36 years; 255 of 520 participants (49.0°6) had never received antiretroviral therapy, and 251 of 484 participants (51.9°6) with available data had a baseline CD4 count of 50 cells per cubic millimeter or less. Six participants withdrew from the trial, and five were lost to follow-up. During the 12 months of follow-up, death occurred in 116 of 263 participants (44.10/0) in tile clexaillethasorle group and irl 126 of 2-57 pfirticipants (49. 090) in the placebo group (hazard ratio, 0.85; 95% confidence interval, 0. 66 to 1.10; P=0.22). Prespecified analyses did not reveal a subgroup that clearly benefited from dexamethasone. The incidence of secondary end-point events, including cases of immune reconstitution inflammatory syndrome during the first 6 months, was similar in the two trial groups. The numbers of participants with at least one serious adverse event were similar in the dexamethasone group (192 of 263 participants [73.090]) and the placebo group (194 of 257 participants [75.5°6]) (P=0.52). CONCLUSIONS: Among HIV-positive adults with tuberculous meningitis, adjunctive dexamethasone, as compared with placebo, did not confer a benefit with respect to survival or any secondary end point. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Correction: A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults.
- Author
-
Mai NTH, Dobbs N, Phu NH, Colas RA, Thao LTP, Thuong NTT, Nghia HDT, Hanh NHH, Hang NT, Heemskerk AD, Day JN, Ly L, Thu DDA, Merson L, Kestelyn E, Wolbers M, Geskus R, Summers D, Chau NVV, Dalli J, and Thwaites GE
- Published
- 2023
- Full Text
- View/download PDF
7. A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults.
- Author
-
Mai NTH, Dobbs N, Phu NH, Colas RA, Thao LTP, Thuong NTT, Nghia HDT, Hanh NHH, Hang NT, Heemskerk AD, Day JN, Ly L, Thu DDA, Merson L, Kestelyn E, Wolbers M, Geskus R, Summers D, Chau NVV, Dalli J, and Thwaites GE
- Subjects
- Adult, Antitubercular Agents adverse effects, Aspirin adverse effects, Combined Modality Therapy adverse effects, Double-Blind Method, Drug-Related Side Effects and Adverse Reactions epidemiology, Drug-Related Side Effects and Adverse Reactions pathology, Female, Fibrinolytic Agents adverse effects, Humans, Male, Mental Disorders epidemiology, Mental Disorders prevention & control, Middle Aged, Placebos administration & dosage, Survival Analysis, Treatment Outcome, Antitubercular Agents administration & dosage, Aspirin administration & dosage, Combined Modality Therapy methods, Fibrinolytic Agents administration & dosage, HIV Infections complications, Tuberculosis, Meningeal drug therapy
- Abstract
Adjunctive dexamethasone reduces mortality from tuberculous meningitis (TBM) but not disability, which is associated with brain infarction. We hypothesised that aspirin prevents TBM-related brain infarction through its anti-thrombotic, anti-inflammatory, and pro-resolution properties. We conducted a randomised controlled trial in HIV-uninfected adults with TBM of daily aspirin 81 mg or 1000 mg, or placebo, added to the first 60 days of anti-tuberculosis drugs and dexamethasone (NCT02237365). The primary safety endpoint was gastro-intestinal or cerebral bleeding by 60 days; the primary efficacy endpoint was new brain infarction confirmed by magnetic resonance imaging or death by 60 days. Secondary endpoints included 8-month survival and neuro-disability; the number of grade 3 and 4 and serious adverse events; and cerebrospinal fluid (CSF) inflammatory lipid mediator profiles. 41 participants were randomised to placebo, 39 to aspirin 81 mg/day, and 40 to aspirin 1000 mg/day between October 2014 and May 2016. TBM was proven microbiologically in 92/120 (76.7%) and baseline brain imaging revealed ≥1 infarct in 40/114 (35.1%) participants. The primary safety outcome occurred in 5/36 (13.9%) given placebo, and in 8/35 (22.9%) and 8/40 (20.0%) given 81 mg and 1000 mg aspirin, respectively (p=0.59). The primary efficacy outcome occurred in 11/38 (28.9%) given placebo, 8/36 (22.2%) given aspirin 81 mg, and 6/38 (15.8%) given 1000 mg aspirin (p=0.40). Planned subgroup analysis showed a significant interaction between aspirin treatment effect and diagnostic category (P
heterogeneity = 0.01) and suggested a potential reduction in new infarcts and deaths by day 60 in the aspirin treated participants with microbiologically confirmed TBM (11/32 (34.4%) events in placebo vs. 4/27 (14.8%) in aspirin 81 mg vs. 3/28 (10.7%) in aspirin 1000 mg; p=0.06). CSF analysis demonstrated aspirin dose-dependent inhibition of thromboxane A2 and upregulation of pro-resolving CSF protectins. The addition of aspirin to dexamethasone may improve outcomes from TBM and warrants investigation in a large phase 3 trial., Competing Interests: NM, ND, NP, RC, LT, NT, HN, NH, NH, AH, JD, LL, DT, LM, EK, MW, RG, DS, NC, JD, GT No competing interests declared, (© 2018, Mai et al.)- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.